Meropenem Qilu (Meropenem)

Meropenem is a broad‑spectrum carbapenem antibiotic used for serious bacterial infections in the hospital setting.

• Complicated intra‑abdominal infections: provides rapid bacterial clearance in severe abdominal sepsis.
• Complicated urinary tract infections: eradicates resistant uropathogens causing upper‑tract infection.
• Nosocomial pneumonia: treats ventilator‑associated and hospital‑acquired lung infections.
• Meningitis: penetrates the cerebrospinal fluid to eliminate causative bacteria.
• Septicemia: offers systemic coverage against Gram‑negative and Gram‑positive pathogens.

• Meropenem inhibits bacterial cell‑wall synthesis by binding with high affinity to penicillin‑binding proteins (PBPs). This binding blocks the final transpeptidation step of peptidoglycan cross‑linking, leading to weakened cell walls and bacterial lysis. The drug is stable against most β‑lactamases, allowing activity against a wide range of resistant Gram‑negative and Gram‑positive organisms.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: erythematous skin eruption.
• Headache: transient mild headache.
• Elevated liver enzymes: transient increase in ALT/AST.
• Injection site reactions: pain or erythema at infusion site.

Serious or Rare Side Effects

• Seizures: especially in patients with CNS disorders or renal impairment.
• Clostridioides difficile colitis: severe diarrhea due to gut flora disruption.
• Anaphylaxis: acute allergic reaction with hypotension and airway compromise.
• Severe neutropenia: marked reduction in white blood cells.
• Renal toxicity: worsening kidney function in susceptible patients.
• Hepatic failure: rare but potentially life‑threatening liver injury.

Careful assessment and monitoring are required when using Meropenem.

• Renal function monitoring: adjust dose in patients with impaired clearance.
• Hypersensitivity screening: avoid in individuals with known carbapenem allergy.
• Seizure risk: use cautiously in patients with CNS disease or a history of seizures.
• Hepatic impairment: monitor liver enzymes during prolonged therapy.
• Concomitant nephrotoxic drugs: increase vigilance for renal adverse events.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough.
• Other carbapenems: concurrent use can increase toxicity without added benefit.
• High‑dose aminoglycosides: combined nephrotoxic potential.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may enhance renal clearance of meropenem.
• NSAIDs: monitor for additive renal effects.
• Warfarin: possible alteration of INR, require coagulation monitoring.
• Oral contraceptives: reduced effectiveness, advise backup contraception.
• Other antibiotics: potential antagonism, assess clinical response.